BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38558822)

  • 1. Discovering single cannabidiol or synergistic antitumor effects of cannabidiol and cytokine-induced killer cells on non-small cell lung cancer cells.
    Li Y; Sharma A; Hoffmann MJ; Skowasch D; Essler M; Weiher H; Schmidt-Wolf IGH
    Front Immunol; 2024; 15():1268652. PubMed ID: 38558822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Expression of Cannabinoid Receptor 2 on Cytokine-Induced Killer Cells and Multiple Myeloma Cells.
    Garofano F; Schmidt-Wolf IGH
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant cytokine-induced killer cell immunotherapy improves long-term survival in patients with stage I-II non-small cell lung cancer after curative surgery.
    Huang J; Zhao X; Zhang Z; Yang S; Chen X; Shen C; Wang L; Qi Y; Zhang Y
    Cytotherapy; 2023 Feb; 25(2):202-209. PubMed ID: 36379882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines.
    Li Y; Sharma A; Wu X; Weiher H; Skowasch D; Essler M; Schmidt-Wolf IGH
    Front Oncol; 2022; 12():713476. PubMed ID: 35646685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
    Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Low Dose of Pure Cannabidiol Is Sufficient to Stimulate the Cytotoxic Function of CIK Cells without Exerting the Downstream Mediators in Pancreatic Cancer Cells.
    Garofano F; Sharma A; Abken H; Gonzalez-Carmona MA; Schmidt-Wolf IGH
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
    Tao L; Huang G; Shi S; Chen L
    Med Oncol; 2014 Jan; 31(1):777. PubMed ID: 24271420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.
    Zhao P; Bu X; Wei X; Sun W; Xie X; Li C; Guo Q; Zhu D; Wei X; Gao D
    Int Immunopharmacol; 2015 Apr; 25(2):450-6. PubMed ID: 25698555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials.
    Xiao Z; Wang CQ; Feng JH; Zhou MH; Wang YZ; Li NN; Sun YP; Liu SY; Yao XS; Li CW; Ma B; Ding J; Chen L
    Cytotherapy; 2019 Feb; 21(2):125-147. PubMed ID: 30554868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
    Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
    Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
    Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
    Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer.
    Wang M; Cao JX; Pan JH; Liu YS; Xu BL; Li D; Zhang XY; Li JL; Liu JL; Wang HB; Wang ZX
    PLoS One; 2014; 9(11):e112662. PubMed ID: 25412106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol Increases Proliferation, Migration, Tubulogenesis, and Integrity of Human Brain Endothelial Cells through TRPV2 Activation.
    Luo H; Rossi E; Saubamea B; Chasseigneaux S; Cochois V; Choublier N; Smirnova M; Glacial F; Perrière N; Bourdoulous S; Smadja DM; Menet MC; Couraud PO; Cisternino S; Declèves X
    Mol Pharm; 2019 Mar; 16(3):1312-1326. PubMed ID: 30721081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2.
    Morelli MB; Offidani M; Alesiani F; Discepoli G; Liberati S; Olivieri A; Santoni M; Santoni G; Leoni P; Nabissi M
    Int J Cancer; 2014 Jun; 134(11):2534-46. PubMed ID: 24293211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer.
    Wang S; Wang Z
    Int Immunopharmacol; 2015 Sep; 28(1):22-8. PubMed ID: 26013109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
    Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
    PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials.
    Xiao Z; Wang CQ; Zhou MH; Li NN; Liu SY; He YJ; Wang YZ; Feng JH; Yao XS; Chen L; Ma B; Yu S; Zeng XT; Li CW; Ding J
    Int Immunopharmacol; 2018 Aug; 61():363-375. PubMed ID: 29945024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC.
    Song H; Liu S; Zhao Z; Sun W; Wei X; Ma X; Zhao P; Gao D
    Int Immunopharmacol; 2017 Nov; 52():197-202. PubMed ID: 28941416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study.
    Han Y; Mu D; Liu T; Zhang H; Zhang J; Li S; Wang R; Du W; Hui Z; Zhang X; Ren X
    Thorac Cancer; 2021 Jan; 12(2):145-152. PubMed ID: 33150733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy with sequential cytokine-induced killer (CIK) cells in stage IB non-small cell lung cancer.
    Li DP; Li W; Feng J; Chen K; Tao M
    Oncol Res; 2015; 22(2):67-74. PubMed ID: 25706393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.